Latest news
- Business15 June 2021
Alvotech reaches primary completion date in its switching study for AVT02, a proposed interchangeable biosimilar to AbbVie's Humira®
Alvotech’s Proposed Interchangeable Product for High-Concentration Humira® Could Save U.S. Consumers and Taxpayers Billions Annually In May of 2021, Alvotech USA Inc. Sued to End AbbVie’s Wrongful Monopoly on Humira...
- Business08 June 2021
Robert Wessman presented at the Jefferies Global Healthcare Conference
Róbert Wessman, Chairman of Alvotech, presented at the Jefferies Global Healthcare Conference, that took place in virtual format on June 1-4, 2021.
- Charity07 June 2021
Alvotech employees donate to UNICEF Covid relief in India
The latest outbreak of Covid-19 in India, hit close to home for Alvotech employees as many colleagues have relocated to Iceland from India to join the company. In a gesture...
- Business11 May 2021
Alvotech seeks to end AbbVie’s wrongful monopoly on Humira and bring affordable arthritis treatment to U.S.
Federal Court Filing Details AbbVie’s Continued Attempts to Squash Competition Over America’s Highest Grossing Prescription Drug Alvotech’s New Biosimilar Drug Would Provide Immediate Savings to Consumers Alvotech today filed a...
- Charity10 May 2021
Alvotech proud sponsor of Reykjavik’s football club KR
Alvotech and the Icelandic sports club KR have signed a collaboration agreement for the 2021 season. Robert Wessman, Chairman of Alvotech and Pall Kristjansson, Head of KR’s football division, signed...
- Business25 March 2021
Alvotech disputes AbbVie’s allegations of wrongdoing
Alvotech strongly disputes AbbVie’s allegations of wrongdoing relating to AVT02, Alvotech’s proposed biosimilar to HUMIRA® (adalimumab).
- Business15 March 2021
Alvotech completes second round of a US$ 100m private placement
Alvotech has successfully completed a second round of its US$ 100 million private placement, for US$ 35 million.
- Charity05 March 2021
Alvotech and sister company Alvogen donate 100 thousand US dollars to UNICEF
Birna Thórarinsdóttir, Executive Director at UNICEF Iceland, and Robert Wessman, the Chairman and Founder Alvotech, signed a collaboration agreement today, under which the companies, Alvotech and sister company Alvogen will...
- Business02 March 2021
Cipla Gulf and Alvotech expand partnership for commercialization of biosimilars in Australia and New Zealand
Cipla Gulf and Alvotech today announced that they are expanding their partnership for the marketing and distribution of four biosimilar medicines in Australia and New Zealand.
- Business25 February 2021
Alvotech Iceland receives Equal Pay Certification
The Equal pay certification follows a rigorous process requiring specific policies, processes and controls to be implemented.
- Business30 December 2020
Ground-breaking for the extension of Alvotech's high-tech centre in Reykjavik
A ground-breaking ceremony for the extension of Alvotech's high-tech centre in Reykjavík took place today. Robert Wessman, Chairman of the Board, Dagur B. Eggertsson, Mayor of Reykjavik and Jon Atli...
- Business10 December 2020
Alvotech and Fuji Pharma extend biosimilar partnership in Japan
Fuji Pharma will exclusively commercialize the medicines in Japan – discussions between the parties continue over additional biosimilar candidates
- Business24 November 2020
Alvotech & CCHT Biopharmaceutical and Yangtze River Pharmaceutical
Alvotech hf. and Alvotech & CCHT Biopharmaceutical Co., Ltd., which is the China joint venture company of Alvotech hf. and Changchun High & New Technology Industries (Group) Inc., have partnered...
- Business19 November 2020
U.S. FDA and EMA have accepted regulatory submissions for AVT02 - Alvotech
Alvotech is developing AVT02 as a proposed biosimilar to HUMIRA® (adalimumab) with high concentration (100mg/mL) dosage forms AVT02 is highly similar to its reference product in terms of structure and...
- Business04 November 2020
Alvotech and Cipla partner to ensure access to biosimilars in South Africa
Alvotech and Cipla Medpro, a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited, have entered into an exclusive partnership to bring key biosimilars to patients in emerging markets...
- Business27 October 2020
Alvotech announces private placement financing
Alvotech announced today that its parent company, Alvotech Holdings SA, has successfully completed a $65 million private placement round.
- Business22 September 2020
Alvotech and DKSH extend partnership in Asia
Alvotech and DKSH, a leading healthcare provider across 36 emerging countries in South-East Asia, today announced an expansion of their strategic partnership to commercialize six new biosimilar product candidates for...
- Business05 August 2020
Alvotech and Teva announce strategic partnership to collaborate in the U.S. biosimilar market
Alvotech and Teva bring together highly complementary capabilities to secure a leading position in the U.S. biosimilar market The collaboration is one of the broadest partnerships within the U.S....
- People18 May 2020
Tanya Zharov joins Alvotech as Deputy CEO
Alvotech today announced the appointment of Tanya Zharov as deputy chief executive officer in Iceland. Tanya's principal responsibilities will be oversight of Icelandic operations and administration, including the Reykjavik site...
- Business12 May 2020
Alvotech announces positive top-line results for two comparative studies.
Alvotech is developing AVT02 as a proposed biosimilar to HUMIRA® (adalimumab) with high concentration (100mg/mL) dosage forms The Phase 1 PK similarity study for AVT02 (AVT02-GL-101) has met its primary...
- Business05 May 2020
Alvotech and Alvogen launch new B2B business brand
We are excited to announce the launch of our new brand identity for our B2B business, Adalvo. Why ‘Adalvo’? Our B2B business has seen tremendous growth in recent...